Show simple item record

The multicenter real-world report of the efficacies of 14-day esomeprazole-based and rabeprazole-based high-dose dual therapy in first-line Helicobacter pylori eradication in Taiwan

dc.contributor.authorWei-Chen Tai
dc.contributor.authorI-Ting Wu
dc.contributor.authorHsin-Ming Wang
dc.contributor.authorPao-Yuan Huang
dc.contributor.authorChih-Chien Yao
dc.contributor.authorCheng-Kun Wu
dc.contributor.authorShih-Cheng Yang
dc.contributor.authorChih-Ming Liang
dc.contributor.authorPin-I Hsu
dc.contributor.authorSeng-Kee Chuah
dc.contributor.otherDivision of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Taiwan; Chang Gung University College of Medicine, Taiwan
dc.contributor.otherDivision of Gastroenterology, Department of Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan
dc.contributor.otherDivision of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Taiwan
dc.contributor.otherDivision of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Taiwan
dc.contributor.otherDivision of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Taiwan
dc.contributor.otherDivision of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Taiwan; Chang Gung University College of Medicine, Taiwan
dc.contributor.otherDivision of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Taiwan
dc.contributor.otherDivision of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Taiwan; Chang Gung University College of Medicine, Taiwan; Corresponding author. Division of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, 123, Ta-Pei Road, Niao-Sung Hsiang, Kaohsiung, 833 Taiwan.
dc.contributor.otherDivision of Gastroenterology, Department of Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan
dc.contributor.otherDivision of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Taiwan; Chang Gung University College of Medicine, Taiwan
dc.date.accessioned2025-10-09T05:33:19Z
dc.date.available2025-10-09T05:33:19Z
dc.date.issued01-08-2024
dc.identifier.urihttp://www.sciencedirect.com/science/article/pii/S168411822400046X
dc.identifier.urihttp://digilib.fisipol.ugm.ac.id/repo/handle/15717717/41162
dc.description.abstractBackground: High-dose dual therapy (HDDT) using proton-pump inhibitors (PPI) and amoxicillin attracted attention for its simplicity and lower adverse event profile. Besides, vonoprazan is not available worldwide. This real-world study aims to compare the efficacy of esomeprazole-based and rabeprazole-based HDDT regimens and to identify clinical factors influencing outcomes. Methods: A retrospective study enrolled 346 Helicobacter pylori-infected naïve patients from January 2016 to August 2023. Patients were assigned to either a 14-day esomeprazole-based HDDT (EA-14; esomeprazole 40 mg t.i.d. and amoxicillin 750 mg q.i.d. for 14 days, n = 173) or a 14-day rabeprazole-based HDDT (RA-14; rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days, n = 173). Results: Five patients from the EA-14 group and 10 from the RA-14 group were lost to follow-up, resulting in 168 and 163 patients for the per-protocol (PP) analysis, respectively. Eradication rates for the EA-14 and RA-14 groups were 90.2% and 80.9% (P = 0.014) in intention-to-treat (ITT) analysis; and 92.9% and 85.9% (P = 0.039) in PP analysis. Adverse event rates were similar between the two groups (11.9% vs 11.7%, P = 0.944). In multiple logistic regression analysis, age≧60 was associated with eradication failure (P = 0.046) and a trend of significance for smoking (P = 0.060) in the EA-14 group but not in the RA-14 group. A trend of significance was also observed for eradication regimens (EA-14 vs RA-14) (P = 0.071).The antibiotic resistance rates were amoxicillin (2.3%), clarithromycin (14.7%), metronidazole (40.3%), and dual resistance to clarithromycin and metronidazole (7.0%). Conclusions: Esomeprazole-based HDDT achieved over 90% eradication rates but rabeprazole-based HDDT, which failed.
dc.language.isoEN
dc.publisherElsevier
dc.subject.lccMicrobiology
dc.titleThe multicenter real-world report of the efficacies of 14-day esomeprazole-based and rabeprazole-based high-dose dual therapy in first-line Helicobacter pylori eradication in Taiwan
dc.typeArticle
dc.description.keywordsHelicobacter pylori infection
dc.description.keywordsEsomeprazole
dc.description.keywordsRabeprazole
dc.description.keywordsHigh dose dual therapy
dc.description.keywordsAntibiotic susceptibility
dc.description.pages601-608
dc.description.doi10.1016/j.jmii.2024.02.009
dc.title.journalJournal of Microbiology, Immunology and Infection
dc.identifier.oaioai:doaj.org/journal:1c33ef16ceec47d4b5996f3996b41daf
dc.journal.infoVolume 57, Issue 4


This item appears in the following Collection(s)

Show simple item record